


(R)-PR-924

| | | | |
|---------------------------|---|-------|----------|
| Cat. No.: | HY-123587A | | |
| Molecular Formula: | C ₃₇ H ₃₈ N ₄ O ₅ | | |
| Molecular Weight: | 618.72 | | |
| Target: | Others | | |
| Pathway: | Others | | |
| Storage: | Powder | -20°C | 3 years |
| | | 4°C | 2 years |
| | In solvent | -80°C | 6 months |
| | | -20°C | 1 month |



SOLVENT & SOLUBILITY

In Vitro

DMSO : 125 mg/mL (202.03 mM; Need ultrasonic)

| Concentration | Mass | | | |
|---------------|-----------|-----------|------------|--|
| | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.6162 mL | 8.0812 mL | 16.1624 mL | |
| 5 mM | 0.3232 mL | 1.6162 mL | 3.2325 mL | |
| 10 mM | 0.1616 mL | 0.8081 mL | 1.6162 mL | |

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description

(R)-PR-924 is the isomer of PR-924 (HY-123587), and can be used as an experimental control. PR-924 is a selective tripeptide epoxyketone immunoproteasome subunit LMP-7 inhibitor with an IC₅₀ of 22 nM. PR-924 covalently modifies proteasomal N-terminal threonine active sites. PR-924 inhibits growth and triggers apoptosis in multiple myeloma (MM) cells. PR-924 has antitumor activities^{[1][2]}.

REFERENCES

- [1]. Singh AV, et al. PR-924, a selective inhibitor of the immunoproteasome subunit LMP-7, blocks multiple myeloma cell growth both in vitro and in vivo. *Br J Haematol.* 2011 Jan;152(2):155-63.
- [2]. Parlati F, et al. Carfilzomib can induce tumor cell death through selective inhibition of the chymotrypsin-like activity of the proteasome. *Blood.* 2009 Oct 15;114(16):3439-47.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA